Turn Funding Signals into Pipeline
Fundz analyzes real-time funding events through YOUR lens to surface companies most likely to buy — with the “why now” built in.
Minerva Biotechnologies announced it raised $4.52 Million in an initial filing from an offering of $8 Million
Amount Raised
$4.52 Million
Round Type
seed
WalthamBiotechnologyCompany Information
Location
40 BEAR HILL ROAD
Waltham, Massachusetts, United States
About
Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. NCT04020575 is Minerva’s first-in-human trial of huMNC2-CAR44, a CAR T that targets the MUC1* growth factor receptor, for the treatment of metastatic breast cancers, 95% of which express a MUC1*. We are now expanding the current clinical trial to include our second CAR-T product that greatly increases persistence. The Company is rapidly accelerating its pipeline that includes next-gen CAR-T products, a straight antibody therapeutic and a small molecule therapeutic which are both for the treatment of cancer metastasis. Our track record of scientific breakthroughs is a testament to our visionary team and our collaborative culture. Join us in changing the world.
Company News
(4 articles)Breakthrough in Patient-Derived Stem Cells for Therapeutic Regenerative Medicine - Business Wire
Minerva CEO navigates 'nightmare' lab market to secure new HQ in Woburn - The Business Journals
Minerva Biotechnologies, Interview with CEO Dr. Cynthia Bamdad - BioInformant
Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor Cancers - Business Wire
FundzWatch™ Score
Related People
Sign in to view contact details
Sign in to view contact details